Trial Profile
A phase III trial of niraparib in combination with TSR-042 in patients with non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a TESARO Inc. media release, this trial is expected to initiate in the second half of 2018.